Sign in
Taking peoplePhase 1

Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER)

Key facts

Who runs it
Rigshospitalet
Where
Denmark3 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 1
People taking part
384 people, planned
Started
26 Feb 2025
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
13 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Fluent in Danish or English language
  • Admission to ICU for severe acute brain injury after trauma, a cerebrovascular accident or anoxic-ischemic/metabolic injury (typically after cardiac arrest) causing coma or another acute DoC (i.e., UWS/VS, MCS), diagnosed by trained investigators
  • Unconsciousness is expected by the attending physicians to last for ≥3 days
  • Written informed consent for trial participation from both the trial guardian and next-of-kin

Who cannot take part

  • Known severe psychotic disorder (e.g., schizophrenia, psychosis after drug abuse, psychotic major depression, current major depression, bipolar disease, but previous history of major depression without psychosis allowed) or a history of a first-degree relative with such a disorder
  • Deafness, blindness, or bilateral eye surgery before the onset of brain injury
  • Ongoing use of dopamine agonists or antagonists within 6 half-lives of the drug
  • Ongoing or previous use of psychoactive or psychotropic substances (including, but not limited to monoamine oxidase inhibitors or medications that are known as uridine diphosphate glucuronosyltransferase enzyme modulators; and ongoing treatments with selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors medications because of the potential to increase the risk of serotonin syndrome) 2 weeks prior examination or within 6 half-lives of the drug
  • Recovery of the ability to follow commands consistently prior to enrolment
  • Cardiac valvular disease and pulmonal hypertension (for a theoretical concern that serotonergic agents might aggravate these conditions)
  • Ongoing infusion of sedatives/continuous pharmacological sedation (We aim for unsedated patients during neurological examinations, pupillometry and NIRS-EEG, but if patients cannot fully be weaned from sedation, dosages are reduced to the lowest possible level.)
  • Lack of Danish or English language proficiency
  • Lack of next-of-kin consent
  • Residency outside of Denmark
  • Expected survival <7 days
  • Females of childbearing potential, unless negative HCG test is present

This trial is currently available in Denmark.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To do a dose escalation study to establish the safety of utilizing apomorphine and psilocybin in unresponsive ICU patients with acute brain injury. This is a prospective, open-label, phase 1b, dose escalation study (n=80 patients, i.e., 26 patients with 1 mg psilocybin, 27 patients with 10 mg, and 27 patients with 25 mg psilocybin; all 80 patients receive apomorphine 1-2h after psilocybin administration). The study is authorized and registered as EU-CT 2023-503617-30-02 and is currently recruiting patients as of June 2026. NB: The earlier version EU-CT 2023-503617-30-01 referred to under “Justification for trial category” was subsequently modified after request from the Ethics committee.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
13 August 2026